228 related articles for article (PubMed ID: 33767379)
1. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.
Zhao ZA; Jiang Y; Chen YY; Wu T; Lan QS; Li YM; Li L; Yang Y; Lin CT; Cao Y; Zhou PZ; Guo JY; Tian YX; Pang JX
Acta Pharmacol Sin; 2022 Jan; 43(1):121-132. PubMed ID: 33767379
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Zhao Z; Liu J; Kuang P; Luo J; Surineni G; Cen X; Wu T; Cao Y; Zhou P; Pang J; Zhang Q; Chen J
Eur J Med Chem; 2022 Feb; 229():114092. PubMed ID: 34998055
[TBL] [Abstract][Full Text] [Related]
3. Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase.
Chen Y; Zhao Z; Li Y; Yang Y; Li L; Jiang Y; Lin C; Cao Y; Zhou P; Tian Y; Wu T; Pang J
Phytomedicine; 2021 Jan; 80():153374. PubMed ID: 33075645
[TBL] [Abstract][Full Text] [Related]
4. Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway.
Li Y; Zhao Z; Luo J; Jiang Y; Li L; Chen Y; Zhang L; Huang Q; Cao Y; Zhou P; Wu T; Pang J
Phytomedicine; 2021 Jul; 87():153585. PubMed ID: 34044255
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological evaluation of a novel skeleton compound isobavachin (4',7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity.
Zhao Z; Luo J; Liao H; Zheng F; Chen X; Luo J; Chen Y; Zhao K; Zhang S; Tian J; Wu T; Li Y; Li L; Yang Y; Lin C; Zhang Q; Tian Y; Pang J
Bioorg Chem; 2023 Apr; 133():106405. PubMed ID: 36753966
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Tan PK; Liu S; Gunic E; Miner JN
Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
[TBL] [Abstract][Full Text] [Related]
7. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
Zhang X; Wu J; Liu W; Liu Y; Xie Y; Shang Q; Zhou Z; Xu W; Tang L; Wang J; Zhao G
Med Chem; 2017; 13(3):260-281. PubMed ID: 27633583
[TBL] [Abstract][Full Text] [Related]
9. Renal Reabsorptive Transport of Uric Acid Precursor Xanthine by URAT1 and GLUT9.
Arakawa H; Amezawa N; Kawakatsu Y; Tamai I
Biol Pharm Bull; 2020; 43(11):1792-1798. PubMed ID: 33132325
[TBL] [Abstract][Full Text] [Related]
10. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.
Anzai N; Ichida K; Jutabha P; Kimura T; Babu E; Jin CJ; Srivastava S; Kitamura K; Hisatome I; Endou H; Sakurai H
J Biol Chem; 2008 Oct; 283(40):26834-8. PubMed ID: 18701466
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.
Novikov A; Fu Y; Huang W; Freeman B; Patel R; van Ginkel C; Koepsell H; Busslinger M; Onishi A; Nespoux J; Vallon V
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F173-F185. PubMed ID: 30427222
[TBL] [Abstract][Full Text] [Related]
12. Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia.
Zhang Y; Jin L; Liu J; Wang W; Yu H; Li J; Chen Q; Wang T
J Ethnopharmacol; 2018 Mar; 214():29-36. PubMed ID: 29233733
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
Zhao Z; Liu J; Yuan L; Yang Z; Kuang P; Liao H; Luo J; Feng H; Zheng F; Chen Y; Wu T; Guo J; Cao Y; Yang Y; Lin C; Zhang Q; Chen J; Pang J
Eur J Med Chem; 2022 Nov; 242():114682. PubMed ID: 36001935
[TBL] [Abstract][Full Text] [Related]
14. (E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1.
Hu Q; Zhou M; Zhu H; Lu G; Zheng D; Li H; Hao K
Biomed Pharmacother; 2017 Feb; 86():88-94. PubMed ID: 27951420
[TBL] [Abstract][Full Text] [Related]
15. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents.
Ao GZ; Zhou MZ; Li YY; Li SN; Wang HN; Wan QW; Li HQ; Hu QH
Bioorg Med Chem; 2017 Jan; 25(1):166-174. PubMed ID: 28340987
[TBL] [Abstract][Full Text] [Related]
17. DKB114, A Mixture of
Lee YS; Kim SH; Yuk HJ; Kim DS
Nutrients; 2018 Sep; 10(10):. PubMed ID: 30274153
[No Abstract] [Full Text] [Related]
18. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Li X; Yan Z; Tian J; Zhang X; Han H; Ye F
Ann Clin Lab Sci; 2019 Nov; 49(6):756-762. PubMed ID: 31882426
[TBL] [Abstract][Full Text] [Related]
19. Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.
Zhao T; Meng Q; Sun Z; Chen Y; Ai W; Zhao Z; Kang D; Dong Y; Liang R; Wu T; Pang J; Liu X; Zhan P
J Med Chem; 2020 Oct; 63(19):10829-10854. PubMed ID: 32897699
[TBL] [Abstract][Full Text] [Related]
20. Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.
Cai W; Wu J; Liu W; Xie Y; Liu Y; Zhang S; Xu W; Tang L; Wang J; Zhao G
Molecules; 2018 Jan; 23(2):. PubMed ID: 29382075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
